Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development

Kondapuram, Sree Karani; Ramachandran, Hema Kasthuri; Arya, Hemant; Coumar, Mohane Selvaraj

doi:10.1016/j.lfs.2023.122260

Cited by 9 publications

(5 citation statements)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in researches of patients with breast cancer, lymphoid leukemia and melanoma, BIRC5 can be recognized by cytotoxic T lymphocytes and generate immune response 39 . BIRC5 can also promote tumor resistance to broad-spectrum chemotherapy drugs, radiation insensitivity, and lead to poor prognosis 40 , 41 . Given the importance of BIRC5 in tumors, many clinical studies on small molecule inhibitors targeting it are ongoing.…”

Section: Discussionmentioning

confidence: 99%

“…Given the importance of BIRC5 in tumors, many clinical studies on small molecule inhibitors targeting it are ongoing. Although some of these inhibitors have shown certain therapeutic effects, off target effects often occur 40 . It is gratifying that immunotherapy based on BIRC5 is gradually receiving attention, and some survivin vaccines have entered clinical research, which may provide new options for cancer treatment in the future 42 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exploring effective biomarkers and potential immune related gene in small cell lung cancer

Yunchu,

Miyanaga,

Matsuda

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is well known as a highly malignant neuroendocrine tumor. Immunotherapy combined with chemotherapy has become a standard treatment for extensive SCLC. However, since most patients quickly develop resistance and relapse, finding new therapeutic targets for SCLC is important. We obtained four microarray datasets from the Gene Expression Omnibus database and screened differentially expressed genes by two methods: batch correction and “RobustRankAggregation”. After the establishment of a protein–protein interaction network through Cytoscape, seven hub genes (AURKB, BIRC5, TOP2A, TYMS, PCNA, UBE2C, and AURKA) with high expression in SCLC samples were obtained by eight CytoHubba algorithms. The Least Absolute Shrinkage and Selection Operator regression and the Wilcoxon test were used to analyze the differences in the immune cells’ infiltration between normal and SCLC samples. The contents of seven kinds of immune cells were considered to differ significantly between SCLC samples and normal samples. A negative association was found between BIRC5 and monocytes in the correlation analysis between immune cells and the seven hub genes. The subsequent in vitro validation of experimental results showed that downregulating the expression of BIRC5 by siRNA can promote apoptotic activity of SCLC cells and inhibit their vitality, migration, and invasion. The use of BIRC5 inhibitor inhibited the vitality of SCLC cells and increased their apoptotic activity. BIRC5 may be a novel therapeutic target option for SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Exploring effective biomarkers and potential immune related gene in small cell lung cancer

Yunchu,

Miyanaga,

Matsuda

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In conjunction with apoptosis regulation, we found survivin, an anti-apoptotic family member of the inhibitor of apoptosis proteins (IAPs; for review see [79]), to be upregulated in GIPR overexpressing Weri cells. Survivin is overexpressed in various tumor entities and its overexpression frequently correlates with cancer progression and recurrence [79]. Increased levels of survivin do, however, not correlate with increased apoptosis levels and reduced tumorigenicity following GIPR overexpression in Weri RB cells.…”

Section: Discussionmentioning

confidence: 99%

GIPR Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells

Haase,

Alefeld,

Yalinci

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In conjunction with apoptosis regulation, we found survivin, an anti-apoptotic family member of the inhibitor of apoptosis proteins (IAPs; for review, see [79]), to be upregulated in GIPR-overexpressing Weri cells. Survivin is overexpressed in various tumor entities, and its overexpression frequently correlates with cancer progression and recurrence [79]. Increased levels of survivin, however, do not correlate with increased apoptosis levels and reduced tumorigenicity following GIPR overexpression in Weri RB cells.…”

Section: Discussionmentioning

confidence: 99%

Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells

Haase,

Alefeld,

Yalinci

et al. 2024

Cancers

View full text Add to dashboard Cite

Retinoblastoma (RB) is the most common malignant intraocular tumor in early childhood. Gene expression profiling revealed that the gastric inhibitory polypeptide receptor (GIPR) is upregulated following trefoil factor family peptide 1 (TFF1) overexpression in RB cells. In the study presented, we found this G protein-coupled transmembrane receptor to be co-expressed with TFF1, a new diagnostic and prognostic RB biomarker for advanced subtype 2 RBs. Functional analyses in two RB cell lines revealed a significant reduction in cell viability and growth and a concomitant increase in apoptosis following stable, lentiviral GIPR overexpression, matching the effects seen after TFF1 overexpression. In chicken chorioallantoic membrane (CAM) assays, GIPR-overexpressing RB cells developed significantly smaller CAM tumors. The effect of GIPR overexpression in RB cells was reversed by the GIPR inhibitor MK0893. The administration of recombinant TFF1 did not augment GIPR overexpression effects, suggesting that GIPR does not serve as a TFF1 receptor. Investigations of potential GIPR up- and downstream mediators suggest the involvement of miR-542-5p and p53 in GIPR signaling. Our results indicate a tumor suppressor role of GIPR in RB, suggesting its pathway as a new potential target for future retinoblastoma therapy.

show abstract

Targeting survivin for cancer therapy: Strategies, small molecule inhibitors and vaccine based therapeutics in development

Cited by 9 publications

References 147 publications

Exploring effective biomarkers and potential immune related gene in small cell lung cancer

Exploring effective biomarkers and potential immune related gene in small cell lung cancer

GIPR Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells

Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells

Contact Info

Product

Resources

About